Biomarkers in chimeric antigen receptor T-cell therapy

Weimin Kong^{1

2

3}, Simon F Lacey^{1

2

3}, Jan Joseph Melenhorst^{1

2

3}, Joseph A Fraietta^{1

2

3}

Affiliations

¹ Department of Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
² Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA 19104, USA.
³ Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia 19104, PA, USA.

Editorial

Weimin Kong et al. Biomark Med. 2018 May.

. 2018 May;12(5):415-418.

doi: 10.2217/bmm-2018-0054. Epub 2018 Apr 26.

Weimin Kong^{1

2

3}, Simon F Lacey^{1

2

3}, Jan Joseph Melenhorst^{1

2

3}, Joseph A Fraietta^{1

2

3}

¹ Department of Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
² Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA 19104, USA.
³ Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia 19104, PA, USA.

No abstract available

Keywords: CAR; CTL019; Kymriah; T cell; Tisagenlecleucel; biomarker; cancer; cell therapy; immunotherapy; translational medicine.

Publication types